



ACCADEMIA NAZIONALE DI MEDICINA

17<sup>th</sup> MEET THE PROFESSOR

# *Advanced International Breast Cancer Course (AIBCC)*

*LIVE WEBINAR & IN-CLASS COURSE*

SEPTEMBER 30<sup>TH</sup>, 2021 H.14.45-17.30

OCTOBER 1<sup>ST</sup>, 2021 H.10.00-18.10

[www.accmed.org](http://www.accmed.org)



GYMNASIVM  
MNIVM DISCIPLINA

PRINCIPE PASCHALI CICONIA  
PRÆSIDIO IOANNE SVPERANTIO EQ· ET FEDERICO  
REFORMATORIBVS IO·FRANC·PRIOLO DOCTORE, ZACHA  
LEONARDO DONATO EQ· INSTAVRATVM ANNO M

## *Aims*

Mortality from breast cancer is declining in most countries thanks to effective screening programs, early diagnosis, molecular characterization of the different subtypes and biology-driven treatments. A multidisciplinary management of breast cancer patients is therefore the key to success and a breast multidisciplinary team should include - besides the "classic" clinical specialties - pathologists, molecular biologists and geneticists. Furthermore, the availability of multiple diagnostic and therapeutic choices, the increasing costs of new technologies and drugs and the issue of sustainability represent a new challenge for socially-responsible clinicians. With this goal in mind, the Programme includes lectures on molecular characterization, updated treatments of early and advanced disease, management of difficult cases and hereditary syndromes and issues of sustainability and drug access across countries.

## *Addressed to*

Gynaecologists and obstetrics, medical oncologists, pathologists, radiologists, radiation oncologists, surgeons. Biologists, pharmacists, and nurses.

# Thursday, September 30<sup>th</sup> 2021

*International speakers will be connected from various countries and local speakers will be present at the meeting venue.*

14.45 **Introduction to the Conference**

Pier Franco Conte, Gabriel N. Hortobagyi, Valentina Guarneri, Philip Poortmans

**SESSION I**

Chairpersons: Hesham Ahmed Gaballah Elghazaly, Pier Franco Conte

15.00 **Obesity and cancer**

Roberto Vettor

15.20 **Management of women BRCA1/2 and other predisposition gene mutations**

Shani Paluch-Shimon

15.40 **Axillary dissection: still an option?**

Eleftherios Mamounas

16.00 **Hot topics in breast cancer RT**

Philip Poortmans

16.20 **Clinical impact of genomics in BC**

Aleix Prat

16.40 **PIK3CA testing: from technical aspects to clinical application**

Sybille Loibl

17.00 **Prognostic signatures to guide treatment decision**

Gabriel N. Hortobagyi

17.20 **Q&A**

17.30 **Adjourn**

# Friday, October 1<sup>st</sup> 2021

International speakers will be connected from various countries and local speakers will be present at the meeting venue.

## **SESSION II –MULTIDISCIPLINARY TUMOR BOARD**

Chairperson: Pier Franco Conte, Valentina Guarneri

- 10.00 **Clinical case 1: Omission of RT in elderly patients with low-risk tumor**  
Franco Berti
- 10.20 **Clinical case 2: cT1c, cN0 HER2+tumor: neo vs adjuvant (option to escalate or de-escalate therapy)**  
Cristina Falci
- 10.40 **Clinical case 3: Post-neoadjuvant therapy in patients with RD (stressing the concept of RCB and characterization of RD)**  
Federica Miglietta
- 11.00 **Clinical case 4: oligometastatic disease**  
Grazia Vernaci
- 11.20 **Clinical case 5: Brain mets**  
Gaia Griguolo
- 11.40 **Clinical case 6: when to stop active therapy**  
Carlo Alberto Giorgi
- 12.00 *Lunch*

## **SESSION III**

Chairpersons: Jacek Jassem, Valentina Guarneri

- 14.30 **Adjuvant CDK4/6i for HR+ disease: reconciling data from randomized trials**  
Valentina Guarneri

- 14.50 **Early BRCAm tumors: PARPi are coming!**  
Pier Franco Conte
- 15.10 **Neoadjuvant therapy for early breast cancer:  
beyond the pCR dogma**  
Pier Franco Conte
- 15.30 **Immunotherapy for early TNBC: hopes and hypes**  
Hope Rugo
- 15.50 **Q&A**
- 16.10 **Treatment algorithm for HER2+ ABC**  
Sandra Swain
- 16.30 **Targeting unconventional pathways in Luminal BC**  
Maria Vittoria Dieci
- 16.50 **Treatment algorithm for HR+/HER2- ABC**  
Stephen Johnston
- 17.10 **Antibody Drug Conjugates for BC**  
Frederik Marmè
- 17.30 **Treatment algorithm and new options for TN ABC**  
Miguel Martin
- 17.50 **Q&A**
- 18.10 **Adjourn**

# *Access Mode*

To ensure compliance with the health event provisions relating to Covid-19, AIBCC 2021 will be held both as in-class course and as a live webinar. When registering, it is necessary to select the desired participation method, until exhaustion of available places. Registration for the activity can only take place online, no registrations will be accepted at the congress venue. AccMed reserves the right to carry out the event exclusively in digital mode if the situation of the health emergency from Covid-19 makes it necessary. In this case, AccMed will be responsible for informing speakers and participants of the change in the way the event is going to be held.

## *Live webinar*

The Live Webinar will allow participants to attend to AIBCC 2021 from anywhere in the world.

The Live Webinar, with the participation of speakers connected from various countries, is addressed to both Italian and foreign participants. The official language of the course is English. No simultaneous translation will be provided.

To follow the webinar, participants will need a good quality internet connection and a device (PC, Smartphone, Tablet) capable of running a recent Internet browser (e.g. any updated version of Chrome or Firefox).

## *In-Class Course*

The in-class course will take place at the venue specified underneath. Please note that due to COVID mitigation measures, the availability of places for the in-presence course is limited.

The in-class course, with the participation of speakers connected from various countries and local speakers present at the meeting venue, is addressed primarily to Italian participants. The official language of the course is English. No simultaneous translation will be provided.

## *CME Webinar live*

Based on the in force regulations approved by the CNFC, Accademia Nazionale di Medicina (provider n. 31) will assign to the activity CME (**31-324301**): **12 CME points**.

Training objective: professional and technical content (knowledge and skills) specific to each profession, specialisation and highly specialised activity. Rare disease.

The credit certification for the webinar is subject to:

- Professions/specializations should correspond to those which have been accredited for CME
- attendance at the 100% of the async distance learning and webinar live on the platform [fad.accmec.org](http://fad.accmec.org);
- the completion of the Meeting evaluation online form;
- completion of the final test (at least 75% of correct answers). 5 attempts admitted.

The test and the meeting evaluation form must be completed within 3 days from the end of the event.

## *CME In-Class Course*

Based on the in force regulations approved by the CNFC, Accademia Nazionale di Medicina (provider n. 31) will assign to the activity CME (**31-324769**): **8 CME points**.

Training objective: professional and technical content (knowledge and skills) specific to each profession, specialisation and highly specialised activity. Rare disease.

The credit certification for the webinar is subject to:

- Professions/specializations should correspond to those which have been accredited for CME;
- attendance at the 90% of the meeting;
- completion of the meeting evaluation online form;
- completion of the final test (at least 75% of correct answers).  
1 attempt admitted.

The test and the meeting evaluation form must be completed within 3 days from the end of the event.

# Directors

## **Pier Franco Conte**

*Division of Medical Oncology 2  
Istituto Oncologico Veneto IRCCS  
Department of Surgery, Oncology and  
Gastroenterology  
University of Padova (I)*

## **Valentina Guarneri**

*Division of Medical Oncology 2  
Istituto Oncologico Veneto IRCCS  
Department of Surgery, Oncology and  
Gastroenterology  
University of Padova (I)*

## **Gabriel N. Hortobagyi**

*Department of Breast Medical Oncology  
The University of Texas -  
MD Anderson Cancer Center  
Houston (USA)*

## **Philip Poortmans**

*Former president of ESTRO and of ECCO  
Department of Radiation Oncology  
Iridium Netwerk  
University of Antwerp  
Wilrijk-Antwerp (B)*

# Scientific Committee

## **Hesham Ahmed Gaballah Elghazaly**

*Department of Clinical Oncology  
and nuclear medicine  
University of Ainshams  
Cairo (EG)*

## **Jacek Jassem**

*Department of Oncology and Radiotherapy  
Medical University of Gdansk (PL)*

## **Stephen Johnston**

*NIHR Biomedical Research Centre for Cancer  
Royal Marsden NHS Foundation  
Trust & Institute of Cancer Research  
London (UK)*

## **Sibylle Loibl**

*German Breast Group  
University of Frankfurt (D)*

## **Eleftherios Mamounas**

*Comprehensive Breast Program  
MD Anderson Cancer Center Orlando  
Orlando (F)*

## **Miguel Martin**

*Medical Oncology Service  
Hospital Universitario Gregorio Marañon  
Madrid (E)*

## **Stefania Migliuolo**

*Europa Donna Italia  
Milan (I)*

## **Fedro Alessandro Peccatori**

*Department of Medical Oncology  
European Institute of Oncology (IEO)  
Milan (I)*

## **Aleix Prat**

*Medical Oncology Department  
Hospital Clinic  
Barcelona (E)*

## **Sandra M. Swain**

*Research Development  
Georgetown University Medical Center  
Washington (USA)*



# Speakers

## **Franco Berti**

*Department of Radiation Oncology  
Istituto Oncologico Veneto IRCCS  
Department of Surgery, Oncology and  
Gastroenterology  
University of Padua (I)*

## **Pier Franco Conte**

*Division of Medical Oncology 2  
Istituto Oncologico Veneto IRCCS  
Department of Surgery, Oncology and  
Gastroenterology  
University of Padova (I)*

## **Maria Vittoria Dieci**

*Division of Medical Oncology 2  
Istituto Oncologico Veneto IRCCS  
Department of Surgery, Oncology and  
Gastroenterology  
University of Padova (I)*

## **Cristina Falci**

*Division of Medical Oncology 2  
Istituto Oncologico Veneto IRCCS  
Department of Surgery, Oncology and  
Gastroenterology  
University of Padua (I)*

## **Carlo Alberto Giorgi**

*Division of Medical Oncology 2  
Istituto Oncologico Veneto IRCCS  
Department of Surgery, Oncology and  
Gastroenterology  
University of Padua (I)*

## **Gaia Griguolo**

*Division of Medical Oncology 2  
Istituto Oncologico Veneto IRCCS  
Department of Surgery, Oncology and  
Gastroenterology  
University of Padua (I)*

## **Valentina Guarneri**

*Division of Medical Oncology 2  
Istituto Oncologico Veneto IRCCS  
Department of Surgery, Oncology and  
Gastroenterology  
University of Padova (I)*

## **Gabriel N. Hortobagyi**

*Department of Breast Medical Oncology  
The University of Texas -  
MD Anderson Cancer Center  
Houston (USA)*

## **Stephen Johnston**

*NIHR Biomedical Research Centre for Cancer  
Royal Marsden NHS Foundation Trust &  
Institute of Cancer Research  
London (UK)*

## **Sibylle Loibl**

*German Breast Group  
University of Frankfurt (D)*

## **Eleftherios Mamounas**

*Comprehensive Breast Program  
MD Anderson Cancer Center Orlando  
Orlando (F)*

## **Frederik Marmè**

*National Center for Tumor Diseases (NCT)  
University of Heidelberg (DE)*

## **Miguel Martin**

*Medical Oncology Service  
Hospital Universitario Gregorio Marañon  
Madrid (E)*

## **Federica Miglietta**

*Division of Medical Oncology 2  
Istituto Oncologico Veneto IRCCS  
Department of Surgery, Oncology and  
Gastroenterology  
University of Padua (I)*

**Shani Paluch-Shimon**

*Sharet Institute of Oncology  
Hadassah University Hospital  
Jerusalem (IL)*

**Philip Poortmans**

*Former president of ESTRO and of ECCO  
Department of Radiation Oncology  
Iridium Network  
University of Antwerp  
Wilrijk-Antwerp (B)*

**Alex Prat**

*Medical Oncology Department  
Hospital Clinic  
Barcelona (E)*

**Hope Rugo**

*UCSF Carol Franc Buck Breast Care Center  
Breast Oncology Clinical Trials Program  
San Francisco (USA)*

**Sandra M. Swain**

*Research Development  
Georgetown University Medical Center  
Washington (USA)*

**Grazia Vernaci**

*Division of Medical Oncology 2  
Istituto Oncologico Veneto IRCCS  
Department of Surgery, Oncology and  
Gastroenterology  
University of Padua (I)*

**Roberto Vettor**

*Division of Internal Medicine  
University of Padova (I)*

# *Registration*

€ 180,00

€ 100,00 for graduate students and nurses

Online registration at <http://meettheprofessor.accmed.org> **before 20 September**; the application will be completed only after the payment of the registration fee.

## **CANCELLATION**

In order to cancel please give advise with a written communication to Accademia Nazionale di Medicina within 10 days from the beginning. A 70% of the registration fee will be returned. Any cancellation after that deadline will not be reimbursed.

# *Meeting venue In-Class Course*

Four Points by Sheraton  
Corso Argentina, 5  
Padova

## *Under 40*

Free admission is available for a few people "under 40".

Registration forms will be accepted on a first-come, first-served basis until spaces will be full.

The Organization Secretariat will confirm the registration by email.

*Supported by unrestricted  
educational grants from*

GOLD SPONSOR



SILVER SPONSOR



BRONZE SPONSOR



CONTRIBUTORS



# With the patronage of

## INSTITUTIONS



REGIONE DEL VENETO



Comune di Padova

1222-2022  
**800**  
ANNI



UNIVERSITÀ  
DEGLI STUDI  
DI PADOVA



**Rete Oncologica Veneta**  
Ricerca, innovazione, assistenza



SCIENTIFIC SOCIETIES





*Organizer*

**ACCADEMIA NAZIONALE  
DI MEDICINA**



General Manager: Stefania Ledda  
[www.accmed.org](http://www.accmed.org)

**Information:**

<http://meettheprofessor.accmed.org>  
Ph. 0039 051 0569163 – 051 6360080  
[info.bologna@accmed.org](mailto:info.bologna@accmed.org)

*Organizing Partner*

**Forum Service**  
Via Martin Piaggio, 17/8  
16122 Genova